FGFR2 and cholangiocarcinoma: It is available for the treatment of cholangiocarcinoma in the United States and is under regulatory review for the treatment of previously treated unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement in the EU.